|Articles|September 8, 2021
- Applied Clinical Trials-09-01-2021
- Volume 30
- Issue 9
Applied Clinical Trials September 2021 Issue (PDF)
Click the title above for a link to open the Applied Clinical Trials September 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 5 years ago
A Look Back: How Far Clinical Trial Technology Has Comealmost 5 years ago
Driving Clinical Speed and Agility Post-COVIDalmost 5 years ago
Sample Size Re-Estimation as an Adaptive Designalmost 5 years ago
Building Relationships Key for Smaller Sponsorsalmost 5 years ago
Rebadging Gains Momentum Amidst COVIDalmost 5 years ago
The Post-Pandemic CRO Landscapealmost 5 years ago
Amplifying Patient Voices in Protocol Designalmost 5 years ago
The State of IRT and RTSM Technologiesalmost 5 years ago
Rhetoric and Realism Colliding on EU Discussions of Drug Repurposingalmost 5 years ago
Could Technology Supplant CROs?Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market
2
ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation
3
ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch
4
Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial
5